Novo Holdings Acquires Ellab from EQT Private Equity
June 21, 2023
Novo Holdings A/S has agreed to acquire Ellab from EQT Mid Market Europe (EQT Private Equity); the deal was announced in June and subsequently completed following regulatory approvals. Headquartered in Hillerød, Denmark, Ellab is a provider of validation and monitoring hardware, software and services for the biotech and pharmaceutical industries; the Lundbeck Foundation has also agreed to acquire a significant minority stake.
- Buyers
- Novo Holdings A/S, Lundbeck Foundation
- Targets
- Ellab
- Sellers
- EQT Mid Market Europe (EQT Private Equity), Co-shareholders
- Industry
- Medical Devices
- Location
- Capital Region of Denmark, Denmark
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
EQT Acquires Majority Stake in Ellab from IK Investment Partners
August 7, 2019
Medical Devices
EQT Mid Market Europe has agreed to acquire a majority interest in Ellab A/S from the IK VIII Fund (advised by IK Investment Partners). EQT will partner with Ellab's management, which will retain a minority stake, to accelerate global growth by expanding R&D, enhancing the go-to-market model in the US and Europe, and growing the company's as-a-service offerings.
-
Ellab Acquires PharmaSys, Inc.
May 3, 2023
Healthcare Services
Ellab has acquired PharmaSys, Inc., a Raleigh, North Carolina-based validation and CQV services firm with 17 employees, as part of Ellab's strategy to expand its US field services in the biopharma sector. The PharmaSys owners, Nancy K. Lankford and Charles L. Lankford, will remain through the transition before retiring this summer.
-
Novo Nordisk Acquires Cardior Pharmaceuticals from EQT Life Sciences
March 25, 2024
Biotechnology
Novo Nordisk has agreed to acquire Cardior Pharmaceuticals for up to EUR 1.025 billion, including an upfront payment and contingent development and commercial milestone payments. Cardior, a Hannover-based clinical-stage biotech focused on RNA-targeted therapies for cardiovascular disease, is currently majority-backed by EQT Life Sciences; the deal is expected to close in Q2 2024 subject to regulatory approvals.
-
Novo Holdings Acquires BBI Group
June 15, 2021
Medical Devices
Novo Holdings A/S has agreed to acquire BBI Group from Exponent for an enterprise value of over GBP 400 million, becoming the company's majority shareholder. BBI, a Crumlin, South Wales–headquartered supplier of diagnostics reagents, lateral flow development and diagnostic manufacturing services with more than 400 employees, will benefit from Novo Holdings' life-sciences expertise to pursue organic and inorganic growth.
-
Novo Holdings Invests $72 Million in LanzaTech
August 6, 2019
Biotechnology
Novo Holdings A/S made a $72 million Series E growth equity investment in LanzaTech to support expansion and commercialization of the company's carbon-recycling fuels and chemicals platform. Anders Bendsen Spohr of Novo Holdings will join LanzaTech's board as the investment aims to accelerate deployment of LanzaTech's sustainable fuels, chemicals and polyethylene produced from recycled carbon.
-
Adelis Equity Partners Becomes Majority Owner of Nordic BioSite Group
May 28, 2021
Healthcare Services
Adelis Equity Partners has acquired a majority stake in Nordic BioSite Group to accelerate the group's growth and pan‑European expansion of its life‑science research and diagnostics distribution platform. Tellacq Partners, together with the founders and management team, had built the group (including Nordic Biosite AB, Sanbio BV and Biomol GmbH); the parties did not disclose the purchase price.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.